Synergistic interactions between tamoxifen and trastuzumab (Herceptin).
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D017209:Apoptosis; D002453:Cell Cycle; D002455:Cell Division; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005434:Flow Cytometry; D016193:G1 Phase; D006801:Humans; D015151:Immunoblotting; D020287:In Situ Nick-End Labeling; D010455:Peptides / Q000737:chemistry; D016192:Resting Phase, Cell Cycle; D016196:S Phase; D015398:Signal Transduction; D013629:Tamoxifen / Q000494:pharmacology*; D013997:Time Factors; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D010455:Peptides; D013629:Tamoxifen; D000068878:Trastuzumab